BNC Korea Co., Ltd. (256840.KQ)
KRW 4160.0
(-1.42%)
KRW 4160.0
(-1.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 31.97 Billion KRW | 108.41% |
| 2022 | 15.34 Billion KRW | 36.61% |
| 2021 | 11.23 Billion KRW | 16.08% |
| 2020 | 9.67 Billion KRW | -2.54% |
| 2019 | 9.92 Billion KRW | 5.97% |
| 2018 | 9.36 Billion KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.05 Billion KRW | 71.87% |
| 2024 Q1 | 6.58 Billion KRW | -14.63% |
| 2023 FY | 31.97 Billion KRW | 108.41% |
| 2023 Q3 | 8.8 Billion KRW | -11.59% |
| 2023 Q4 | 7.71 Billion KRW | -12.32% |
| 2023 Q1 | 5.5 Billion KRW | -12.94% |
| 2023 Q2 | 9.95 Billion KRW | 80.85% |
| 2022 Q2 | 2.66 Billion KRW | -6.44% |
| 2022 FY | 15.34 Billion KRW | 36.61% |
| 2022 Q4 | 6.32 Billion KRW | 80.01% |
| 2022 Q3 | 3.51 Billion KRW | 31.92% |
| 2022 Q1 | 2.84 Billion KRW | -9.7% |
| 2021 FY | 11.23 Billion KRW | 16.08% |
| 2021 Q3 | 2.77 Billion KRW | 0.0% |
| 2021 Q4 | 3.15 Billion KRW | 13.48% |
| 2020 FY | 9.67 Billion KRW | -2.54% |
| 2019 FY | 9.92 Billion KRW | 5.97% |
| 2018 FY | 9.36 Billion KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 82.98 Billion KRW | 61.465% |
| CMG Pharmaceutical Co., Ltd. | 43.7 Billion KRW | 26.828% |
| Celltrion Pharm, Inc. | 116.95 Billion KRW | 72.659% |
| Huons Global Co., Ltd. | 417.8 Billion KRW | 92.346% |
| DongKook Pharmaceutical Co., Ltd. | 405.04 Billion KRW | 92.105% |
| Enzychem Lifesciences Corporation | 3.29 Billion KRW | -870.947% |
| Humedix Co., Ltd. | 68.04 Billion KRW | 53.004% |
| Boditech Med Inc. | 76.7 Billion KRW | 58.31% |
| EuBiologics Co., Ltd. | 32.65 Billion KRW | 2.085% |
| FutureChem Co.,Ltd | 758.27 Million KRW | -4117.234% |
| Huons Co., Ltd. | 285.93 Billion KRW | 88.816% |
| AptaBio Therapeutics Inc. | 78.49 Million KRW | -40636.996% |